Dendritic Cell-Based Immunotherapy for Solid Tumors.
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 44.0%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
Dendritic cells (DCs) are key antigen-presenting cells that connect innate and adaptive immunity, influencing tumor microenvironments by activating T cells, NK, and NKT cells, and directly killing tum
APA
Baumrucker C, Relation T, Czerniecki BJ (2026). Dendritic Cell-Based Immunotherapy for Solid Tumors.. Surgical oncology clinics of North America, 35(2), 271-283. https://doi.org/10.1016/j.soc.2025.10.005
MLA
Baumrucker C, et al.. "Dendritic Cell-Based Immunotherapy for Solid Tumors.." Surgical oncology clinics of North America, vol. 35, no. 2, 2026, pp. 271-283.
PMID
41903989 ↗
Abstract 한글 요약
Dendritic cells (DCs) are key antigen-presenting cells that connect innate and adaptive immunity, influencing tumor microenvironments by activating T cells, NK, and NKT cells, and directly killing tumor cells. They are being explored as immunotherapies in cancers like melanoma, breast, prostate, brain, and blood cancers with over 300 clinical trials to date. Intratumoral injection shows promise for its direct effects. The only FDA-approved DC therapy, sipuleucel-T, increases survival in prostate cancer. Further DC trials are ongoing, often combining DCs with other available immunotherapies. Early-stage disease is an emerging target for DC therapy. Further research is needed to optimize these approaches.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.